enGene Holdings Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr '25 Apr 30, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020
Selling, General & Admin	24.95	23.98	9.6	3.96	3.41	3.24
Research & Development	63.01	38.32	16.46	15.47	12.46	10.61
Operating Expenses	87.95	62.3	26.06	19.43	15.87	13.85
Operating Income	-87.95	-62.3	-26.06	-19.43	-15.87	-13.85
Interest Expense	-2.99	-2.8	-4.95	-1.42	-5.02	-3.7
Interest & Investment Income	11.62	10.41	1.12	0.13	0.03	0.06
Currency Exchange Gain (Loss)	-0.31	-0.11	-0.13	-0.7	-0.1	-0.1
Other Non Operating Income (Expenses)	-	-	-10.57	-3.02	-4.2	0.97
EBT Excluding Unusual Items	-79.63	-54.8	-40.6	-24.44	-25.17	-16.63
Other Unusual Items	-	-0.37	-59.3	-	1.73	1.56
Pretax Income	-79.63	-55.16	-99.9	-24.44	-23.44	-15.07
Income Tax Expense	0.25	-0.02	0.02	0.02	-	-
Net Income	-79.88	-55.14	-99.92	-24.46	-23.44	-15.07
Preferred Dividends & Other Adjustments	-	-	4.82	4.56	-1.19	1.58
Net Income to Common	-79.88	-55.14	-104.74	-29.02	-22.25	-16.65
Shares Outstanding (Basic)	48	38	1	1	4	3
Shares Outstanding (Diluted)	48	38	1	1	4	3
Shares Change (YoY)	199.07%	5355.08%	5.72%	-81.61%	28.93%	-
EPS (Basic)	-1.68	-1.46	-151.22	-44.30	-6.25	-6.02
EPS (Diluted)	-1.68	-1.46	-151.22	-44.30	-6.25	-6.02
Free Cash Flow	-75.98	-49.21	-25.06	-17.75	-16.23	-13.25
Free Cash Flow Per Share	-1.59	-1.30	-36.18	-27.09	-4.56	-4.80
EBITDA	-87.81	-62.21	-25.89	-19.19	-15.6	-13.59
D&A For EBITDA	0.14	0.09	0.18	0.24	0.27	0.26
EBIT	-87.95	-62.3	-26.06	-19.43	-15.87	-13.85

Updated Jun 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q